Home LiteratureArticle Details
PMID: 11483779 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro.

Journal of virology ·Vol. 75 ·No. 17 ·2001-09-00 ·Pages 8340-7

Parren PW, Marx PA, Hessell AJ, Luckay A, Harouse J, Cheng-Mayer C, Moore JP, Burton DR

Abstract

A major unknown in human immunodeficiency virus (HIV-1) vaccine design is the efficacy of antibodies in preventing mucosal transmission of R5 viruses. These viruses, which use CCR5 as a coreceptor, appear to have a selective advantage in transmission of HIV-1 in humans. Hence R5 viruses predominate during primary infection and persist throughout the course of disease in most infected people. Vaginal challenge of macaques with chimeric simian/human immunodeficiency viruses (SHIV) is perhaps one of the best available animal models for human HIV-1 infection. Passive transfer studies are widely used to establish the conditions for antibody protection against viral challenge. Here we show that passive intravenous transfer of the human neutralizing monoclonal antibody b12 provides dose-dependent protection to macaques vaginally challenged with the R5 virus SHIV(162P4). Four of four monkeys given 25 mg of b12 per kg of body weight 6 h prior to challenge showed no evidence of viral infection (sterile protection). Two of four monkeys given 5 mg of b12/kg were similarly protected, whereas the other two showed significantly reduced and delayed plasma viremia compared to control animals. In contrast, all four monkeys treated with a dose of 1 mg/kg became infected with viremia levels close to those for control animals. Antibody b12 serum concentrations at the time of virus challenge corresponded to approximately 400 (25 mg/kg), 80 (5 mg/kg), and 16 (1 mg/kg) times the in vitro (90%) neutralization titers. Therefore, complete protection against mucosal challenge with an R5 SHIV required essentially complete neutralization of the infecting virus. This suggests that a vaccine based on antibody alone would need to sustain serum neutralizing antibody titers (90%) of the order of 1:400 to achieve sterile protection but that lower titers, around 1:100, could provide a significant benefit. The significance of such substerilizing neutralizing antibody titers in the context of a potent cellular immune response is an important area for further study.

MeSH Terms
Administration, Intravaginal Animals Antibodies, Monoclonal/administration & dosage,immunology Female HIV/immunology,pathogenicity HIV Antibodies/administration & dosage,blood,immunology HIV Infections/immunology,prevention & control Humans Immunization, Passive Immunoglobulin G/administration & dosage,immunology Macaca Neutralization Tests RNA, Viral/blood Simian Acquired Immunodeficiency Syndrome/immunology,prevention & control Simian Immunodeficiency Virus/immunology,pathogenicity Vaginal Discharge/immunology
Chemicals
Antibodies, Monoclonal HIV Antibodies Immunoglobulin G RNA, Viral
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Parren P W
Departments of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA.
Marx P A
Hessell A J
Luckay A
Harouse J
Cheng-Mayer C
Moore J P
Burton D R
References (42)
42 references, click to expand
  1. Erratum to "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design".
    Immunol Lett. 1997 Jul;58(2):125-32 PMID: 9271324
  2. Preferential coreceptor utilization and cytopathicity by dual-tropic HIV-1 in human lymphoid tissue ex vivo.
    J Clin Invest. 1999 Sep;104(5):R7-R11 PMID: 10487781
  3. HIV-1 entry at the mucosal surface: role of antibodies in protection.
    AIDS. 2000;14 Suppl 3:S167-74 PMID: 11086859
  4. The antiviral activity of antibodies in vitro and in vivo.
    Adv Immunol. 2001;77:195-262 PMID: 11293117
  5. Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12.
    J Virol. 2001 Jul;75(14):6692-9 PMID: 11413337
  6. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats.
    J Virol. 1985 Sep;55(3):517-20 PMID: 4020957
  7. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals.
    Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10134-7 PMID: 1719545
  8. Secretory immunity in the female reproductive tract.
    Am J Reprod Immunol. 1994 Jan;31(1):40-6 PMID: 8166946
  9. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1.
    J Virol. 1994 Aug;68(8):4821-8 PMID: 7518527
  10. Immunoglobulin concentrations and antigen-specific antibody levels in cervicovaginal lavages of rhesus macaques are influenced by the stage of the menstrual cycle.
    Infect Immun. 1999 Dec;67(12):6321-8 PMID: 10569744
  11. In vivo adaptation of SHIV(SF162): chimeric virus expressing a NSI, CCR5-specific envelope protein.
    J Med Primatol. 1999 Aug-Oct;28(4-5):164-8 PMID: 10593481
  12. IgG surfaces as an important component in mucosal protection.
    Nat Med. 2000 Feb;6(2):129-30 PMID: 10655090
  13. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection.
    Nat Med. 2000 Feb;6(2):200-6 PMID: 10655110
  14. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies.
    Nat Med. 2000 Feb;6(2):207-10 PMID: 10655111
  15. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells.
    J Virol. 2000 Jul;74(13):6087-95 PMID: 10846092
  16. Identification of gp120 regions targeted by a highly potent neutralizing antiserum elicited in a chimpanzee inoculated with a primary human immunodeficiency virus type 1 isolate.
    J Virol. 2000 Oct;74(20):9749-54 PMID: 11000249
  17. Intravaginal inoculation of rhesus macaques with cell-free simian immunodeficiency virus results in persistent or transient viremia.
    J Virol. 1994 Oct;68(10):6391-400 PMID: 8083977
  18. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody.
    Science. 1994 Nov 11;266(5187):1024-7 PMID: 7973652
  19. Pre- and postexposure protection against human immunodeficiency virus type 1 infection mediated by a monoclonal antibody.
    J Infect Dis. 1995 May;171(5):1203-9 PMID: 7751695
  20. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.
    J Exp Med. 1995 Jul 1;182(1):185-96 PMID: 7540648
  21. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV).
    Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7490-4 PMID: 7638218
  22. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site.
    AIDS. 1995 Jun;9(6):F1-6 PMID: 7662189
  23. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.
    J Virol. 1995 Nov;69(11):6609-17 PMID: 7474069
  24. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection.
    Cell. 1996 Aug 9;86(3):367-77 PMID: 8756719
  25. Progesterone implants enhance SIV vaginal transmission and early virus load.
    Nat Med. 1996 Oct;2(10):1084-9 PMID: 8837605
  26. The role of a mutant CCR5 allele in HIV-1 transmission and disease progression.
    Nat Med. 1996 Nov;2(11):1240-3 PMID: 8898752
  27. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women.
    Infect Immun. 1997 Apr;65(4):1387-94 PMID: 9119478
  28. Variations in immunoglobulins and IgA subclasses of human uterine cervical secretions around the time of ovulation.
    Clin Exp Immunol. 1996 Jun;104(3):538-42 PMID: 9099941
  29. Quantification of HIV in semen: correlation with antiviral treatment and immune status.
    AIDS. 1997 Jul;11(8):987-93 PMID: 9223732
  30. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1.
    Nat Med. 1997 Dec;3(12):1389-93 PMID: 9396610
  31. Association between culturable human immunodeficiency virus type 1 (HIV-1) in semen and HIV-1 RNA levels in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood.
    J Infect Dis. 1998 Feb;177(2):320-30 PMID: 9466517
  32. Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificity.
    J Virol. 1998 May;72(5):3512-9 PMID: 9557629
  33. Mucosal immunity in the female reproductive tract: correlation of immunoglobulins, cytokines, and reproductive hormones in human cervical mucus around the time of ovulation.
    AIDS Res Hum Retroviruses. 1998 Apr;14 Suppl 1:S51-5 PMID: 9581884
  34. Vaginal transmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks.
    AIDS Res Hum Retroviruses. 1998 Apr;14 Suppl 1:S119-23 PMID: 9581895
  35. Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells.
    J Virol. 1998 Dec;72(12):9788-94 PMID: 9811714
  36. Antibody neutralization-resistant primary isolates of human immunodeficiency virus type 1.
    J Virol. 1998 Dec;72(12):10270-4 PMID: 9811774
  37. Requirement for multiple lymphocyte subsets in protection by a live attenuated vaccine against retroviral infection.
    Nat Med. 1999 Feb;5(2):189-93 PMID: 9930867
  38. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys.
    Nat Med. 1999 Feb;5(2):204-10 PMID: 9930869
  39. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies.
    J Virol. 1999 May;73(5):4009-18 PMID: 10196297
  40. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs.
    Science. 1999 Apr 30;284(5415):816-9 PMID: 10221916
  41. Kinetics of the development of protective immunity in mice vaccinated with a live attenuated retrovirus.
    J Virol. 1999 Oct;73(10):8435-40 PMID: 10482595
  42. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.
    Science. 2000 Oct 20;290(5491):486-92 PMID: 11039923
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
2001-09-00
Pages
8340-7
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC115078
Subset
IM
Grants
NCRR NIH HHS · M01 RR000833 · United States
NHLBI NIH HHS · HL59727 · United States
NIAID NIH HHS · R01 AI041952 · United States
NIAID NIH HHS · AI40377 · United States
NIAID NIH HHS · AI 41952 · United States
NIAID NIH HHS · R37 AI036082 · United States
NIAID NIH HHS · R37 AI033292 · United States
NIAID NIH HHS · R01 AI033292 · United States
NIAID NIH HHS · AI36082 · United States
NIAID NIH HHS · AI33292 · United States
NHLBI NIH HHS · HL59735 · United States
NIAID NIH HHS · R01 AI036082 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com